275 results about "Decreased serum IgA" patented technology

PCT No. PCT / US97 / 06725 Sec. 371 Date Aug. 10, 1998 Sec. 102(e) Date Aug. 10, 1998 PCT Filed Apr. 21, 1997 PCT Pub. No. WO97 / 44314 PCT Pub. Date Nov. 27, 1997The instant invention is new compounds of Formula I their use as cerebrovascular agents in diseases such as stroke, peripheral vascular disease, restenosis, and as agents for regulating plasma cholesterol concentrations, for treating hypercholesterolemia and atherosclerosis, and for lowering the serum or plasma level of Lp(a). A pharmaceutical composition is also claimed.

Compounds that reduce serum retinol, serum RBP, and / or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.

A method for treating hyperglycemia and / or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

The invention relates to the technical field of medicaments and discloses the novel application of a penthorum chinense pursh extract or compounds of ursolic acid, pinocembrin, scopoletin, gallic acid, ursolic acid-28-xylose-(1-3)-glucoside, pinocembrin-7-glucoside, pinocembrin-7-neohesperidoside, scopolin or galloyl glucoside separated from the penthorum chinense pursh extract. Pharmacological and pharmacodynamic tests show that the penthorum chinense pursh extract or the compounds can obviously reduce the rising of aspartate aminotransferase (AST), glutamic-pyruvic transaminase (ALT) and alkaline phosphatase (ALP), caused by acute liver injury, alcoholic liver and virus hepatitis in mice, chronic hepatic fibrosis in rats and the like, has an obvious inhabitation effect on HepG2 tumor cells and can reduce the cholesterol and triglycercide content of blood serum. The penthorum chinense pursh extract or the compounds are simple in preparation method and low in cost. The invention provides a new medicament source for preventing and treating hepatitides, liver injury, hepatic fibrosis, cirrhosis, alcoholic liver, liver cancer and diseases associated with high blood fat.

The invention relates to the field of microorganisms, and particularly relates to Lactobacillus gasseri LG08 with a uric acid degradation effect and application thereof. The Lactobacillus gasseri LG08is preserved in the China General Microbiological Culture Collection Center (CGMCC) in July 18, 2018, with the preservation number being CGMCC No. 16131, and is classified and named as Lactobacillusgasseri, with the preservation address being the Institute of Microbiology, Chinese Academy of Sciences, No.3, Academy No.1, Beichen West Road, Chaoyang District, Beijing. The Lactobacillus gasseri LG08 has an excellent nucleoside and nucleotide degradation capability, can decompose most precursors for uric acid synthesis, reduce the body absorption of precursors for uric acid synthesis and directly and efficiently decompose uric acid in intestinal tracts, and can further inhibit the generation of uric acid and relieve inflammation and other side reactions by reducing the serum endotoxin leveland inhibiting the xanthine oxidase activity.

The invention relates to the technical field of medicine, particularly to applications of chitosan oligosaccharide. According to the present invention, chitosan oligosaccharide is applied in preparation of drugs with functions of weight reduction and / or body fat reduction, and chitosan oligosaccharide with a number average molecular weight of not more than 3000 is preferably selected, wherein the chitosan oligosaccharide with different number average molecular weights provides significant application effects in body weight control, body fat ratio reduction, and reduction of total cholesterol and / or low density lipoprotein cholesterol in blood serum. In addition, the chitosan oligosaccharide has effects of weight reduction, body fat reduction, fatty liver alleviating and reduction of blood fat in blood serum.

The invention belongs to the field of biological detection and specifically relates to a triple test diagnostic kit for breast cancer of tumor serum markers CA125, HE4 and P-her2. The triple test diagnostic kit for breast cancer provided by the invention mainly comprises an abzyme elisa plate, a biotin antibody enveloped plate, bovine serum albumin, serum diluent, horse radish peroxidase, tetramethyl benzidine, sulfuric acid, negative control liquid and positive control liquid. The triple test diagnostic kit for breast cancer provided by the invention can be used for detecting the expression levels of CA125, HE4 and P-her2 in the body of the patient after operative treatment or the relapsing and metastatic tumor patient; the triple test diagnostic kit for breast cancer has important significance in clinical diagnosis of breast cancer; the triple test diagnostic kit for breast cancer provided by the invention can reduce the interference of other matters in serum, can greatly increase the accuracy and stability of detection result and is beneficial to the early diagnosis and prognosis treatment of the patient suffering from breast cancer.

The invention relates to a microbial compound with an effect of relieving irritable bowel syndrome as well as a preparation method and application thereof. The microbial compound with the effect of relieving irritable bowel syndrome comprises animal bifidobacterium subsp. Lactis and lactobacillus acidophilus. The invention creatively develops a new strategy for preventing, relieving or treating the irritable bowel syndrome. The microbial compound can obviously improve the intestinal running function of a patient with the diarrhea-type irritable bowel syndrome, obviously reduce the visceral high sensitivity, obviously reduce the levels of serum inflammatory factors including TNF-alpha, IL-6 and IL-17, obviously improve the level of a serum inflammatory factor IL-10, obviously reduce the levels of serum 5-HT and SP, and obviously improve the colon SERT level. The microbial compound has a great application prospect in the preparation of medicines, foods or health-care products for preventing, treating and relieving the diarrhea-type irritable bowel syndrome.

The invention relates to the technical field of microbes, and discloses a probiotic composition and application thereof. The probiotic composition consists of bifidobacterium adolescentis CCFM8630, lactobacillus reuterii CCFM8631 and lactobacillus rhamnosus CCFM1044, the effect of relieving metabolic syndromes is significantly better than that of CCFM8630 or CCFM8631 used alone and in combination,especially in fields of reducing an epididymal fat content, reducing a fasting blood glucose level, reducing a glucose tolerance curve lower area, lowering a serum low-density lipoprotein and total cholesterol content, increasing the liver antioxidant capacity and reducing a serum IL-1beta content, the decrease or increase of the composition is increased by 9.62%-769.62% compared with a single bacteria or double bacteria combination formula, and the triple bacteria combination can achieve significant synergy.

An application of wogonin in preparing the medicines for preventing and treating hepatitis B by suppressing the copying of HBV DNA and the secretion of s and e antigens of hepatitis B and decreasing the content of HbsAg in serum is disclosed.

The invention discloses application of a polyhydroxy bromo-benzophenone compound and derivatives of the polyhydroxy bromo-benzophenone compound in treatment and prevention of atherosclerosis, and belongs to the technical field of medicines. According to the application of the polyhydroxy bromo-benzophenone compound in the treatment and the prevention of the atherosclerosis, an active ingredient is the polyhydroxy bromo-benzophenone compound 2,4',5'-trihydroxy-5,2'-dibromo-benzophenone, and according to the application of the derivatives of the polyhydroxy bromo-benzophenone compound in the treatment and the prevention of the atherosclerosis, active ingredients are medicinal salt, medicinal ester and medicinal ether of the 2,4',5'-trihydroxy-5,2'-dibromo-benzophenone. Due to the fact that the expression of triglyceride (TG) and low density lipoprotein-cholesterol (LDL-C) in blood serum is reduced, and the expression of inflammatory factors including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and adhesion molecules sICAM-1 in the blood serum is restrained, vascular endothelial injuries are restrained, and vascular endothelia are protected, so that occurrence and development of the atherosclerosis (AS) are restrained, and more broad prospects are opened up for clinical medication.

The invention relates to the technical field of medicines. Chalcone is a natural component in plants and has antibiotic and antifungal effects, and derivatives of the chalcone also have the effect of resisting tumors and the like. At present, no document is reported that the derivatives of the chalcone have the effect of reducing activity of blood fat and protecting the liver. The invention provides derivatives of the dihydrochalcone having a general formula I. Through tests of reducing blood fat, the results show that the derivatives of the dihydrochalcone have the effects of obviously reducing serum total cholesterol and low-density lipoprotein cholesterol, and can be used to prepare medicines or health products for reducing blood fat, preventing and treating hyperlipoidemia, fatty liver, hepatocirrhosis and atherosclerosis and protecting the liver.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 6-40 parts of rheum officinale, 10-95 parts of astragalus and 5-65 parts of salvia miltiorrhiza by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.

The invention relates to a method for preparing black edible fungus anti-hyperglycemic product, belonging to field of preparing polysaccharide. The invention employs black edible fungus deep level liquid fermentation technique, extracts inter-cellular and extra-cellular polysaccharide from deep level fermentation culture, and getting final product through preparation with cell wall-broken treated black edible fungus powder. The product is characterized by apparent functions of reducing serum cholesterol, triglyceride and low-density lipoprotein, and can be used for subsidiary treatment or prevention for hyperlipoidemia.

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

The present invention discloses a fructo-oligosaccharide bovine bone marrow peptide powder composition. The composition comprises fructo-oligosaccharides, bovine marrow peptide powder and probiotic powder. In the fructo-oligosaccharide bovine bone marrow peptide powder composition, functions of the bovine bone marrow peptide powder are mainly hematopoiesis and blood supplementation, contained phosphorus can help calcium precipitation and absorption, and thus improve human body immune system, functions of the fructo-oligosaccharide are promoting expelling of toxins (expelling of liver toxins),lowering serum cholesterol and triglycerides, promoting absorption of calcium and other minerals, and enhancing immune regulation, and functions of the probiotic powder are supplementing losses of probiotics during the toxin expelling process; the process of the fructo-oligosaccharide in lowering the serum cholesterol and triglycerides is the process of removing human body waste, so that an original "body deficiency" is manifested, then the hematopoiesis and blood supplementation of the bovine bone marrow peptide powder enable human body immune system to be truly enhanced; and the three substances achieve a very good synergistic effect and the fructo-oligosaccharide bovine bone marrow peptide powder is an excellent blood-supplementing and human-immunity-enhancing health-care product.

The invention discloses a polystictus glycopeptide active component as well as a preparation method and application thereof. The polystictus glycopeptide active component comprises the following steps: preparation of coriolus versicolor mycelium; extraction of the polystictus glycopeptide active component from the coriolus versicolor mycelium; separation, purification and enzymatic hydrolysis of the polystictus glycopeptide active component. The active component is found by comparing the therapeutical effect of the polystictus glycopeptide active component on an acute alcoholic liver injury mouse model to better reduce the vitalities of AST and ALT in serum, reduce the contents of Triglycerid, MDA, NEFA, TC and LDL-TC in the serum, improve the content of HDL-TC in the serum and realize thebetter therapeutical effect of resisting alcoholic liver injury. According to the preparation method disclosed by the invention, active functional factors for preventing and treating the alcoholic liver injury are found from natural food resources; the obtained polystictus glycopeptide active component can reduce indicators of the ALT, the AST, cholesterol, free fatty acid and the like in the serum, and has a good application value and a potential market prospect in aspects of preventing and treating alcoholic liver disease, fatty liver or hyperlipidemia.

The invention relates to a flavone compound using 3- to replace oxygen radical -3 and 4- dimethoxy and having the function of reducing blood fat, belonging to the technical field of medicine. The chemical construction is like the general formula I; wherein, R stands for H, alhyl radical and acyl radical. Shown by animal experiments, the flavone compound has the function of reducing the triglyceride of serum, the cholesterol and the cholesterol level of LDL and can thus prepare into the medicine or health-caring food for treating or preventing cardiovascular diseases such as hyperlipemia, coronary heart disease and atherosclerosis.

The invention relates to the technical field of medicine, particularly to applications of chitosan oligosaccharide. According to the present invention, chitosan oligosaccharide is applied in preparation of drugs with functions of weight reduction and / or body fat reduction, and chitosan oligosaccharide with a number average molecular weight of not more than 3000 is preferably selected, wherein the chitosan oligosaccharide with different number average molecular weights provides significant application effects in body weight control, body fat ratio reduction, and reduction of total cholesterol and / or low density lipoprotein cholesterol in blood serum. In addition, the chitosan oligosaccharide has effects of weight reduction, body fat reduction, fatty liver alleviating and reduction of blood fat in blood serum.

The invention discloses a new application of nucleotide and an application of the nucleotide in preparation of drugs for preventing and treating diseases such as allergic rhinitis or functional food for relieving symptoms of the allergic rhinitis. The nucleotide is a mixture of five nucleotides, namely CMP, AMP, UMP, GMP and IMP. The molecular weight of the nucleotide is small, absorption of the nucleotide taken by a human body is fast, and bioavailability of the nucleotide is high. It is found that the ingestion of the nucleotide can relieve the symptom of allergic rhinitis of mice, relieve splenomegaly caused by allergy, significantly reduce the histamine level in serum and nasal cavity lavage fluid, and effectively regulate inflammatory factors, thereby playing a role in treating allergic diseases. The nucleotide can be used for preparing medicines for preventing and treating diseases such as allergic rhinitis or functional foods for relieving symptoms of allergic rhinitis, and provides a new way for regulating the immune function in a diet intervention mode.

The invention discloses applications of firmicute probiotics in preventing and / or treating diabetes and relevant diseases, specifically, the firmicute probiotics are used or preparing a composition or a preparation. The composition or the preparation has the following one or more applications: (1) preventing and / or treating diabetes; (b) preventing and / or treating cardiovascular diseases; and / or (c) preventing and / or treating obesity. The firmicute probiotics can obviously inhibit the weight increase, reduce the serum glucose level, reduce the blood lipid level, improve the insulin resistance and / or reduce the glycosylated hemoglobin level, and thus the symptoms of diabetes and relevant diseases can be effectively alleviated.

The present invention belongs to the technical field of health-care products, and particularly relates to an anti-ageing health-care product and a detection method thereof. The health-care product is mainly made from ginseng, caulis spatholobi, milkvetch root, tuber fleeceflower stem, coix seed, fructus corni, Indian bread, cassia twig, glossy privet fruit, dendrobium officinale and liquorice root. The detection method is to use a gas chromatograph to detect a TOSC value of the health-care product, so as to judge the anti-aging ability of the health-care product. The anti-aging health-care product has effects in nourishing liver and kidney and invigorating spleen and replenishing Qi, and enhances human body constitution and body immunity function proceed from the internal cause of aging; at the same time, the health-care product also has strong antioxidant activity, and can effectively remove the free radicals in the body by increasing the activity of SOD in serum and decreasing the activity of MDA in serum, and reduce the damage resulted from the free radicals to the human body to reach beauty-maintaining, countenance-preserving and senescence delaying effects.

The invention belongs to the technical field of biological detection, and particularly relates to a lipoprotein (a) detection kit. The lipoprotein (a) detection kit provided by the invention is mainlycomposed of an antibody elisa plate, a biotin antibody coated plate, horse radish peroxidase-streptavidin, lipoprotein (a) series standard substances, a diluent, a cleaning solution, a substrate solution, a developing solution and a stop solution. The lipoprotein (a) detection kit provided by the invention has the advantages of simple operation, high sensitivity and strong anti-interference capability, can effectively reduce the interference of other substances in serum, especially the interference effect of an anti-RF factor on a detection result, and greatly improves the accuracy and stability of the detection result. Meanwhile, the kit can also reduce the phenomenon of inaccurate detection results caused by the difference of the copy number of apolipoprotein (a) molecules KringleIV-2 in lipoprotein (a), and is more beneficial to early diagnosis and prognosis treatment of patients with arteriosclerosis and heart diseases.

The invention provides an animal serum collecting test tube and a serum separator, and relates to the technical field of animal serum collection. The animal serum collecting test tube comprises a vacuum collecting tube, a needle assembly and a filter tube, wherein the needle assembly is arranged at the opening of the top of the vacuum collecting tube and is detachably connected with the vacuum collecting tube. The filter tube is arranged in the vacuum collecting tube, and the blood inlet of the filter tube is connected with the needle assembly to receive the blood drawn from the needle assembly, and micro pores for passing serum are formed in the filter tube. It is not necessary to carry out second time transfer of serum samples when the serum samples are collected by the animal serum collecting test tube, the process of collection and detection of the serum samples is simplified, and the probability that the serum samples are contaminated can be reduced.

The invention discloses a composite fungal intercellular polysaccharide composition with a liver protecting function and a preparation method. The composite fungal intercellular polysaccharide composition comprises 10-45 weight parts of coprinus comatus intercellular polysaccharide, 20-50 weight parts of white fungus intercellular polysaccharide and 20-45 weight parts of hohenbuehelia serotina intercellular polysaccharide. The preparation method comprises the steps of fermenting fungi, crushing the separated mycelia, adding enzyme for reacting, and separating solid and liquid phases; adding distilled water into the solid phase, then performing ultrasonic treatment, adding ethanol liquid, collecting and drying the sediment; concentrating the liquid phase, adding ethanol, standing, centrifuging to separate the sediment; combining the sediments obtained by solid and liquid phase treatment to obtain homogenous intercellular polysaccharides; and mixing the coprinus comatus intercellular polysaccharide, the white fungus intercellular polysaccharide and the hohenbuehelia serotina intercellular polysaccharide obtained by the method respectively to obtain the composite fungal intercellular polysaccharide composition with the liver protecting function. The composition has the advantages of effectively reducing the ALT (alanine aminotransferase) and AST (aspartate aminotransferase) level of serum, obviously reducing the malonaldehyde content of injured liver and obviously promoting biliary excretion so that the function of the injured liver can be recovered.

The invention relates to applications of niclosamide ethanolamine salt and a medicinal composition of the niclosamide ethanolamine salt. After the niclosamide ethanolamine salt and the medicinal composition of the niclosamide ethanolamine salt are applied, an uncoupling effect can be achieved on the kidney tissue mitochondria, the excretion of proteinuria of mice with kidney diseases can be reduced, the glomerular sclerosis and renal tubular injuries can be improved, the level of serum creatinine can be reduced, and therefore, the niclosamide ethanolamine salt and medicinal composition of theniclosamide ethanolamine salt have a certain protection effect for the kidney diseases, and can be used for preventing and treating the kidney diseases.

The invention relates to the field of medicament preparation, and particularly relates to applications of a Periostin gene and a Periostin antibody in preparation of medicaments. The Periostin gene expression is closely relevant to the occurrence and development of NAFLD (Nonalcoholic Fatty Liver Disease) and hyperlipidemia through remarkable expression increase of the Periostin gene in the liver of a high-fat diet-induced obesity mouse, the significant expression rise of Periostin in a patient with fatty liver, and obvious positive correlation between the Periostin and liver TG (Triglyceride) content as well as serum TG content, and the Periostin gene and the Periostin antibody can be used for preparing and screening a NAFLD reagent and a hyperlipidemia reagent. The Periostin antibody can be used for neutralizing Periostin in the obese mouse body, obviously reducing the liver / weight ratio, and the TG content of the liver and serum, therefore, the Periostin antibody achieves the effects of obviously improving the development of the NAFLD and reducing the TG content in serum.

The invention discloses an application of elaeagnus conferta roxb, namely the application of the elaeagnus conferta roxb in preparation of drugs for treating kidney stones, gall-stone and hyperuricemia. In the treatment of the kidney stones, the drug is used for reducing the rate of the kidney stones, improving kidney coefficient, reducing calcium content of the kidney, reducing serum urea nitrogen and reducing serum creatinine. In the treatment of the gall-stone, the elaeagnus conferta roxb is used for treating bile pigment gallstones and cholesterol gallstones; preferably in the treatment of bilirubin gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones, calcium ion content in bile, total bilirubin concentration and free bilirubin concentration in the treatment of the bile pigment gallstones; in the treatment of the cholesterol gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones and the cholesterol content in the bile; and in the treatment of hyperuricemia, the elaeagnus conferta roxb is used for reducing uric acid content in serum. The application of the elaeagnus conferta roxb can be spread to related products of the elaeagnus conferta roxb; and the related product includes a fruit aqueous extract of the elaeagnus conferta roxb, dewatered elaeagnus conferta roxb, capsules, troches, granulas, fruit vinegar, jam and fruit juice.

The invention provides a hypoglycemic peptide, which is provided with an amino acid sequence as shown in SEQ ID NO: 1. The invention also provides a modified peptide of the hypoglycemic peptide. A chemical group, an amino acid, polypeptide, protein or PEG is connected to the N end, C end or intermediate residue of the hypoglycemic peptide. The hypoglycemic peptide provided by the invention can perfect the glucose tolerance of KK-Ay mice, reinforce the glucose utilization ability of the KK-Ay mice, significantly improve the fasting blood glucose and glucose tolerance of the KK-Ay mice, significantly reduce serum total cholesterol and serum triglyceride, significantly perfect the SOD level, reduce the MDA level and protect the body cells against oxygen free radicals, the hypoglycemic peptide has glucose and lipid reducing functions and can resist metabolic syndrome. The hypoglycemic peptide can be used for preparing drugs or healthcare products for treating and / or preventing diabetes or hyperlipidemia.

The invention relates to medical novel applications of cordycepin (3'-deoxyadenosine), and more specifically relates to applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis and atherosclerosis related diseases. It is confirmed by pharmacodynamic experiments that: cordycepin is capable of inhibiting formation of ApoE- / - mice aorta atherosclerotic plaques significantly, reducing serum TC, TG, and LDL-c contents of animals with hyperlipidemia, increasing total antioxidant capacity and SOD activity of animal serum, reducing MDA content, reducing contents of serum interleukin 2 and interleukin 8 significantly, and inhibiting inflammation. It is confirmed by cell experiments that: cordycepin is capable of inhibiting uptake of mononuclear cell RAW267.4 on cholesterol significantly, and promoting flowing of cholesterol out from cells.